Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open‐label study ( ACE ‐ LY ‐003)

Documenti analoghi

• Real‐world experience with CAR‐T therapy in relapsed and refractory follicular lymphoma
  di: Nicolás Triantafilo, et al.
  Pubblicazione: (2025)
• Peripheral blood involvement in extra‐nodal marginal zone lymphoma
  di: Izidore S. Lossos, et al.
  Pubblicazione: (2025)
• Two‐year follow‐up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study
  di: Yuqin Song, et al.
  Pubblicazione: (2025)
• CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma
  di: Emil Arjun Kumar, et al.
  Pubblicazione: (2024)
• Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study
  di: Swetha Kambhampati Thiruvengadam, et al.
  Pubblicazione: (2025)